Acromegaly and Gigantism – Global Drug Forecast and Market Analysis to 2029
All the vital news, analysis, and commentary curated by our industry experts.
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). This GH excess is often a result of a benign GH-secreting pituitary adenoma. Rarely, tumors in other organs can secrete growth hormone-releasing hormone (GHRH), leading to elevation in GH levels in the serum. This triggers the release of anti-apoptotic and mitogenic peptide hormone, insulin-like growth factor 1 (IGF-1). While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentation of the two hormonal diseases is very different. GH excess beginning in adulthood is known as acromegaly and is characterized by an insidious onset and a delayed diagnosis, whereas GH excess beginning during childhood is known as gigantism and is characterized by a dramatic acceleration of growth, leading to an unusually tall stature. Symptoms of acromegaly and gigantism include the development of abnormally large hands and feet, an enlarged tongue, hyperhidrosis, joint pain, tiredness, and headaches. Surgery to remove the pituitary tumor is often offered to patients with acromegaly or gigantism. Pharmacotherapeutic approaches may be employed to increase the efficacy of surgery, or as a monotherapeutic strategy in cases where surgical procedures are not appropriate for the patient. Somatostatin is a cyclic polypeptide hormone that inhibits the secretion of a number of hormones, including that of GH. First-line pharmaceutical products used to treat acromegaly and gigantism are typically somatostatin analogs (SSAs) because the natural version of the hormone has a very short half-life and cannot bring about sustained suppression of GH.
In 1988, Novartis' Sandostatin, became the first SSA to be approved by the FDA. The therapy, which is injected up to four times daily marked the advent of a new effort by drug developers to produce products that are administered less frequently. Since then, the SSA drug class has expanded to include therapies such as Novartis' Sandostatin LAR (long-acting repeatable) Depot (octreotide acetate for injectable suspension), Novartis' Signifor LAR (pasireotide), and Ipsen's Somatuline (lanreotide acetate) Depot which are all injected on a monthly basis. Although SSAs dominate the treatment landscape, Pfizer's GH inhibitor Somavert (pegvisomant) and dopamine agonists, bromocriptine mesylate and cabergoline have also penetrated the market and are used in combination with first-line drugs.
The seven pharmaceutical markets (7MM) covered in this report and forecast model are the US, France, Germany, Italy, Spain, the UK, and Canada. GlobalData estimates that drug sales for acromegaly and gigantism in 2019 were approximately $1.4B across the 7MM. Over the 10-year forecast period, the market is expected to reach $2.2B in 2029, increasing at a CAGR of 4.4%. Growth in the market will be driven by the launch of longer-acting somatostatin analogs, oral therapies, and growth hormone receptor inhibitors, which are used in combination with first-line drugs to provide an effective treatment option for patients with intractable disease.
Key Questions Answered in This Report
What were the key treatments for acromegaly and gigantism 2019?
When will the late stage pipeline products launch in each of the 7MM?
What are the major clinical and environmental unmet needs in the acromegaly and gigantism market?
What are the key opportunities for pharmaceutical companies developing drug candidates for acromegaly and gigantism?
Overview of acromegaly and gigantism, including epidemiology, etiology, pathophysiology, symptoms, diagnosis of the diseases, and treatment strategies.
Annualized acromegaly and gigantism therapeutics market revenue and sales forecast, including discussion of treatment usage patterns in individual patient populations.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the acromegaly and gigantism market.
Pipeline analysis: comprehensive assessment of emerging trends, molecule types represented in the pipeline, and drug delivery systems being developed by pharmaceutical companies. All drug candidates at Phase II and Phase III stages of development are extensively profiled.
Analysis of the current and future market competition, and an insightful review of the key market drivers, opportunities, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The acromegaly and gigantism market was worth $1.4B in 2019. The market is expected to grow at a CAGR of 4.4% from 2019 to 2029, reaching a global value of $2.2B. GlobalData projects that the marketed for acromegaly and gigantism will experience growth driven by the launch of oral therapies, injectable somatostatin analogs that are administered less frequently than the market-leading product, which is Novartis’ Sandostatin LAR Depot.
Low disease awareness and delayed diagnosis is the most significant unmet need in this therapy area. Lack of physician and patient education means that a large percentage of patients treat the symptoms of these conditions without being able to address the cause of the endocrinological abnormalities for many years. Additionally, more patients are expected to undergo surgery which effectively cures the disease in patients whose pituitary tumors can be successfully excised. Market exclusivity for major brands such as Novartis’ Signifor (pasireotide) and Ipsen’s Somatuline Depot (lanreotide acetate), will also be lost during the forecast window, which will allow competitor drug developers to consider producing generic formulations of these market-dominating somatostatin analogs.
No drugs are being specifically developed for gigantism which means that some pipeline agents will not benefit from being used to treat pediatric patients. Oral therapies such as Chiasma’s Mycapssa (octreotide acetate) and Crinetics’ paltusotine are expected to be used to treat younger patients who may not be candidates for surgery or intramuscular injections. For this reason, and the fact that both of these drugs will launch in multiple markets, Mycapssa and paltusotine are expected to become some of the top-selling therapeutics that will enter the acromegaly market between 2019 and 2029. Growth in the market will be driven by the launch of growth hormone receptor inhibitors. Only one marketed drug (Pfizer’s Somavert/pegvisomant) targets this signaling pathway. Although Pfizer’s Somavert is highly effective in inducing biochemical control of acromegaly, the high cost of therapy has led some regulatory bodies to restrict its use, denying a subset of patients from access to this treatment option. Antisense Therapeutics’ atesidorsen sodium, and Ionis Pharma’s IONIS-GHRLRx are growth hormone receptor inhibitors that are expected to be injected less frequently than Pfizer’s Somavert. Furthermore, these drug candidates represent a new molecule type entering the market within the forecast window, as no antisense therapies are currently available for the management of acromegaly and gigantism.
A disadvantage of the market-leading drug, Sandostatin LAR, is that this therapy is injected via the intramuscular route of administration which is associated with pain and discomfort. Furthermore, patients typically receive injections in a clinical setting which is can be inconvenient for individuals who do not live within easy reach of their healthcare provider.
Drug developers are also focusing on producing self-administrable therapies that can increase patients’ compliance. These therapeutics will reduce the need for patients to attend frequent hospital appointments in order to receive treatment.
The top selling drug to enter the market in the forecast period will be Camurus’ octreotide LA, which is expected to become the first long-acting subcutaneously administrable formulation of octreotide. The largest pharmacotherapy market for acromegaly and gigantism in 2019 was the US, which made up 75% of sales in the base year of the forecast window. The dominance of this market will continue, as most patients with acromegaly in the 7MM are diagnosed and treated in the US. In 2029, the US will generate $1.6B.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global acromegaly and gigantism therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for strategic consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Acromegaly and Gigantism: Executive Summary
2.1 Steady Growth Expected in the Acromegaly and Gigantism Market from 2019–2029
2.2 Pharmaceutical Companies Are Focused on Developing Self-Administrable, Convenient Therapies
2.3 Polypharmacy Will Become Increasingly Common in the Management of Patients With Intractable Disease
2.4 Lack of Disease Awareness Causing Delays in Diagnosis Is a Globally Prevalent Unmet Need
2.5 Oral Therapies and Long-Acting Injectable Somatostatin Receptor Agonists Will Become Top-Selling New Market Entrants in 2029
2.6 What Do Physicians Think?
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Prognosis and Quality of Life
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism
5.4.4 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
5.4.5 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
5.4.6 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
5.4.7 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
5.5 Epidemiological Forecast for Acromegaly, 2019–2029
5.5.1 Diagnosed Prevalent Cases of Acromegaly
5.5.2 Sex-Specific Diagnosed Prevalent Cases of Acromegaly
5.5.3 Age-Specific Diagnosed Prevalent Cases of Acromegaly
5.5.4 Diagnosed Prevalent Cases of Acromegaly with Macroadenoma
5.5.5 Diagnosed Prevalent Cases of Acromegaly with Comorbidities
5.5.6 Diagnosed Prevalent Cases of Gigantism
5.5.7 Sex-Specific Diagnosed Prevalent Cases of Gigantism
5.5.8 Age-Specific Diagnosed Prevalent Cases of Gigantism
5.5.9 Diagnosed Prevalent Cases of Gigantism with Macroadenoma
5.5.10 Diagnosed Prevalent Cases of Gigantism with Comorbidities
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.3.1 Treatment Guidelines
6.3.2 Non-pharmacotherapeutic Treatment Options
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
8.2 Increasing Disease Awareness Among Patients and Physicians
8.3 Greater Control Over Treatment-Related Costs Blocking Access to Essential Therapies
8.4 Improving the Efficacy and Side-Effect Profiles of Pharmaceutical Products
8.5 Making Drug Administration More Manageable for Patients
9 Pipeline Assessment
9.2 Somatostatin Receptor Agonists
9.3 Antisense Therapy Growth Hormone Receptor Inhibitors
9.4 Early-Stage Pipeline Products
10 Current and Future Players
10.2 Trends in Corporate Strategy
10.3.2 Portfolio Assessment
10.4.2 Portfolio Assessment
10.5 Sun Pharma
10.5.2 Portfolio Assessment
10.6.2 Portfolio Assessment
10.7.2 Portfolio Assessment
10.8 Antisense Therapeutics
10.8.2 Portfolio Assessment
10.9.2 Portfolio Assessment
10.10 Ionis Pharmaceuticals
10.10.2 Portfolio Assessment
10.11.2 Portfolio Assessment
10.12 Strongbridge Biopharma
10.12.2 Portfolio Assessment
10.13 Enesi Pharma
10.13.2 Portfolio Assessment
10.14.2 Portfolio Assessment
11 Market Outlook
11.1 Global Markets
11.1.2 Drivers and Barriers – Global Issues
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4.2 Key Events
11.4.3 Drivers and Barriers
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Commercial Positioning of Drugs Included in the Forecast Model
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research – KOLs Interviewed for This Report
12.5 Primary Research – Prescriber Survey
12.6 About the Authors
12.6.2 Associate Therapy Area Director
12.6.3 Senior Therapy Area Director
12.6.5 Managing Epidemiologist
12.6.6 Global Director of Therapy Analysis and Epidemiology
12.6.7 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.